

CURRICULUM VITAE

LUIS H. CAMACHO, M.D., M.P.H.

PROFESSIONAL STATUS:

PRESENT TITLE AND AFFILIATION:

Director

Center for Oncology and Blood Disorders
6560 Fannin Street. Suite 1224
Houston, TX 77030
OFF: 713-796-1200
FAX: 713-795-0735
08/2014 to Present

Associate Section Chief of Oncology

Oncology Section, Internal Medicine Service
CHI St. Luke's Health | Baylor St. Luke's Medical Center - Cancer Center
(Formerly St. Luke's Episcopal Hospital – Cancer Center)
6720 Bertner Street
2457 South Braeswood Blvd.
Houston, TX. 77030
Ofc. 832-355-7206
Appt. 832-355-7200
Fax 832-355-7228
08/2012 – 08/2014

PREVIOUS TITLE(S) AND AFFILIATION(S):

Director

Center for Medical Oncology and Blood Disorders
CHI St. Luke's Health | Baylor St. Luke's Medical Center
(Formerly St. Luke's Episcopal Hospital)
2457 South Braeswood Blvd.
Houston, TX. 77030
Ofc. 832-355-7206
Appt. 832-355-7200
Fax 832-355-7228
01/2012 – 08/2014

Medical Director

CHI St. Luke's Health | Baylor St. Luke's Medical Center - Cancer Center
(Formerly St. Luke's Episcopal Hospital – Cancer Center)
6720 Bertner Street
2457 South Braeswood Blvd.
Houston, TX. 77030
Ofc. 832-355-7206
Appt. 832-355-7200
Fax 832-355-7228
04/2012 – 08/2014

Director of Cancer Research

CHI St. Luke's Health | Baylor St. Luke's Medical Center - Cancer Center
(Formerly St. Luke's Episcopal Hospital)
6720 Bertner Street

2457 South Braeswood Blvd.
Houston, TX. 77030
Ofc. 832-355-7206
Appt. 832-355-7200
Fax 832-355-7228
04/2012 – 08/2014

Director

Department of Research

Oncology Consultants, P.A.
925 Gessner Road Suite 600
Houston, Texas
08/2007 – 12/2011

Assistant Professor

Division of Cancer Medicine
Department of Melanoma Medical Oncology
University of Texas M.D. Anderson Cancer Center
1515 Holcombe Boulevard
Faculty Center 11.2000, Unit 0430
Houston, Texas 77030
7/2001 - 08/2007

Assistant Professor

Division of Cancer Medicine
Phase I Program
University of Texas M.D. Anderson Cancer Center
1515 Holcombe Boulevard
Faculty Center 6.3018, Unit 0422
Houston, Texas 77030
7/2001 - 08/2007

CITIZENSHIP AND VISA STATUS:

Colombia, South America
Permanent Resident – United States of America

HOME ADDRESS:

5818 Queensloch Drive
Houston, Texas 77096
Telephone: 713-283-9770

EDUCATION:

Degree-Granting Education

Fellowship in Medical Oncology and Hematology. Joan and Sanford I. Weill Medical College of Cornell University / Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, 2001

Master in Public Health. School of Public Health and Health Sciences. The George Washington University, Washington, DC, 1998

Medical Doctor. Universidad Militar “Nueva Granada”, Bogotá, DC Colombia, South América, 1988

Postgraduate Education:

FELLOWSHIP:

Clinical Fellowship in Hematology and Medical Oncology
Joan and Sanford I. Weill Medical College of Cornell University
Memorial Sloan-Kettering Cancer Center New York, NY
07/1998 – 06/2001

RESIDENCY:

Internal Medicine

Division of General Internal Medicine
Department of Medicine
The George Washington University Medical Center
Washington, DC
07/1996–06/1998

INTERNSHIP

Division of General Internal Medicine
Department of Medicine
The George Washington University Medical Center
Washington, DC
06/1995–06/1996

Clinical Research Assistant

Division of Hematology and Oncology
The George Washington University Medical Center
Washington, DC
01/1993–06/1995

Elective in Hematology and Oncology as exchange visitor

Division of Hematology and Oncology
The George Washington University Medical Center
Washington, DC
04/1992–08/1992

RESIDENCY – INTERNAL MEDICINE

Department of Internal Medicine

Hospital Militar Central
Universidad Militar “Nueva Granada”
Bogotá DC, Colombia, South América,
01/1990–01/1993

SOCIAL SERVICE:

Instituto Nacional de Cancerología, Ministerio de Salud
Pontificia Universidad Javeriana
Bogotá DC, Colombia, South América
12/1988–12/1989

INTERNSHIP:

Hospital Militar Central / Hospital “La Victoria”
Universidad Militar “Nueva Granada”
Bogotá, DC Colombia, South América,
12/1987–12/1988

CREDENTIALS:

Board Certifications:

American Board of Internal Medicine
Internal Medicine: Certified: 1999-2009 Certificate: # 184624

American Board of Internal Medicine
Medical Oncology: Certified: 2011-2021 Certificate: # 184624

Licensure(s)

Active

Colombia, South America, 14-384. (1989)
State of Texas, L2829. (2017)

PREVIOUS APPOINTMENTS:

Division of Cancer Medicine:
Assistant Professor, (tenure track), Department of Melanoma Medical Oncology
Assistant Professor, (tenure track), Phase I Program
Assistant Professor, (tenure track), Department of Investigational Cancer Therapeutics
University of Texas, M.D. Anderson Cancer Center
Houston, Texas, 2001-2007

CURRENT AND PREVIOUS ADMINISTRATIVE APPOINTMENTS:

Member: Texas Society Clinical Oncology
Formerly Texas Society Medical Oncology
Board of Directors - Secretary
Houston, Texas
2013 – Present

Member: Texas Society Clinical Oncology
Formerly Texas Society Medical Oncology
Secretary
Board of Directors - Director At Large
Houston, Texas
2011 - 2018

Chair: St. Luke's Episcopal Hospital Cancer Committee
St. Luke's Episcopal Hospital Cancer Center
Houston, TX
2012 – 08/2014

Member: St. Luke's Episcopal Hospital Cancer Center
Oncology Collaborative Practice Team
Houston, TX
2012 – Present

Member: Harris County Medical Society
HCMS Delegation to the TMA House
Reference Committee Review Team
Houston, Texas
2009 – Present

Member: Texas Society Clinical Oncology
Formerly Texas Society Medical Oncology
Board of Directors - Director At Large
Houston, Texas
2009 - 2012

Member: St. Luke's Episcopal Hospital Cancer Center
Cancer Committee
St. Luke's Episcopal Hospital
Houston, TX
2008 - 2014

Member: Memorial Hermann Cancer Committee
Hermann Memorial / Memorial City Medical Center & Texas Medical Center
Houston, Texas
2008 - 2010

Member: Hematology and Medical Oncology Comprehensive Board Review Course Committee
University of Texas M.D. Anderson Cancer Center / Baylor College of Medicine
Houston, Texas

2002 - 2007

Member: Clinical Research Committee
University of Texas M.D. Anderson Cancer Center
2002 - 2007

Chair: Clinical Research Committee
University of Texas M.D. Anderson Cancer Center
2004 - 2007

Associate Member: Institutional Review Board I (IRB)
University of Texas M.D. Anderson Cancer Center
2005 - 2007

Vice Chair: Institutional Review Board II (IRB)
University of Texas M.D. Anderson Cancer Center
2005 - 2007

HONORS AND AWARDS

American College of Physicians, Poster Winner
Washington DC, Chapter
1996

Internal Review to Division of Hematology and Oncology
George Washington University Medical Center, Resident's Committee
1997

Golden Apple - Teaching Award
American Medical Students Association
George Washington University Medical Center
1997

American College of Physicians
Washington DC Chapter
Certificate of Appreciation for Poster Presentation
1998

American Association for Cancer Research
American Society Cancer Oncology
Methods in Clinical Cancer Research Workshop
2000

The Cancer and Leukemia Group B
Clinical Cancer Research Award
2000

American Society of Clinical Oncology Merit Award
2000

American Society of Clinical Oncology Merit Award
2001

The Ribbon of Hope Foundation Award
2004

National Cancer Institute - Career Development Award
NCI # P50 TA093459. \$50,000
2004

The Goodwin Research Foundation. Clinical Research Award. \$275,000.
2007

CanCare Cancer Support. Spirit of Volunteerism Award.
Houston, Texas
2012

LANGUAGES:

Fluent Spanish and English

SPECIAL INTERESTS:

Drug Development, Design and Conduct of Phase I Studies, Clinical Research, Regional Hepatic Therapies, Solid Tumors, Melanoma

RESEARCH:

**Grants and Contracts
Funded Protocols**

Principal Investigator: Phase 2, Open Label, Randomized Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics, of 2 Regimens of CP-675,206 in Patients with Advanced Melanoma.
11/2001-01/2004

Principal Investigator: A Phase I Open Label Non-Randomized Dose Escalation Study to Evaluate the Safety and Tolerability Pharmacokinetics and Immune Function Effects of CP675, 206 in Subjects with Solid Tumor Malignancies.
01/2002-01/2003

Co-Principal Investigator: Clinical Implications of Retinoid-Induced CD38 Antigen Expression, R01 CA092115 01 A2, Principal Investigator: K. Mehta.
05/2003-04/2007

Principal Investigator: A Phase Ib/II Dose Escalating Biologic Study Evaluating the Anti-angiogenic and Pro-apoptotic activity of ABX-IL8 in Combination with Dacarbazine in Patients with Metastatic Melanoma, P50-CA93459-01.
6/1/2003-5/31/2004

Principal Investigator: A Phase I, Open Label, Non-randomized, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immune Function Effects, and Efficacy of Multiple Doses of CP-675,206 in Patients with Advanced Melanoma.
12/2004-11/2005

Principal Investigator: Immunological Modulation via Cytotoxic T-cell Lymphocyte-associated Antigen-4 (CTLA-4) Blockade in Patients with Advanced Malignant Melanoma.
07/2004-09/2005

Principal Investigator: A Phase I Study Dose Escalation Clinical Study Of Hepatic Intra-arterial Cisplatin, In Combination with Systemic Intravenous Liposomal Doxorubicin Administered Every Four Weeks to Patients With Advanced Cancer and Dominant Liver Involvement, 2004-0568.
03/2005–08/2007

Principal Investigator: Generation of Monoclonal Antibodies Against Antigens Expressed on the Cellular Membranes of Tumor Exposed Peripheral Blood Lymphocytes Isolated from Patients with Different Clinical Stages of Solid Malignancies, mAB Generation, Inc.
6/2005-6/2006

Principal Investigator: A Phase I Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of ZIO-101 in Adult Patients with Advanced Solid Tumors.
7/2005-7/2006

Principal Investigator: A Phase I Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Safety of Satraplatin in Patients with Refractory Non-Hematologic Cancer.
8/2005-8/2006

Principal Investigator: A Phase I Study of the Effects of Renal Impairment on the Pharmacokinetics and Safety of Satraplatin in Patients with Refractory Non-Hematologic Cancer.
8/2005-8/2006

Principal Investigator: A Phase I Study of Paclitaxel Administered by Hepatic Artery Infusion to Patients with Advanced Cancer and Dominant Liver Involvement.
10/2005-08/2007

Principal Investigator: A Phase I Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly x 3.
11/2005-11/2008

Principal Investigator: A Phase I Multi-center, Dose Escalation and Pharmacokinetic Study of L-NDDP (Aroplatin) in Patients with Advanced Solid Malignancies or B-Cell Lymphoma.
3/2006-6/2011

Principal Investigator: A Phase I Study of Hepatic Arterial Infusion of Oxaliplatin in Combination with Systemic Fluorouracil Leucovorin and Avastin for Patients with Advanced Solid Tumors Metastatic to the Liver.
07/2006-08/2007

Principal Investigator: A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V-930 in Patients with Cancers Expressing HER-2 and/or CEA.
09/2006-08/2007

Principal Investigator: A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V-930/V934 in Patients with Cancers Expressing HER-2 and/or CEA Merck.
09/2006-08/2007

Principal Investigator: An Open-Label Phase I Study of the Safety of Perifosine in Combination with Sorafenib for patients with Advanced Cancers.
10/2006-09/2008

Principal Investigator: Randomized, Open-Label, Multicenter Study of Velcade with Rituximab or Rituximab alone in Subjects with Relapsed or Refractory Rituximab Naive or Sensitive Follicular B-cell NHL.
10/2006-10/2008

Principal Investigator: ARIES: An Observational Study of Avastin in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable CRC, Locally Advanced or Metastatic NSCLC, or Locally recurrent or Metastatic Breast Cancer.
01/2007-10/2008

Principal Investigator: A Randomized Placebo-Controlled Study of Perifosine in Combination with Single Agent Chemotherapy for Metastatic Cancer Patients.
02/2007-10/2008

Principal Investigator: A Phase I Dose Escalation Study of MK-2461 in Patients with Advanced Cancer, Merck 2006-0929.

02/2007–08/2007

Principal Investigator: SPIRITT A Multicenter, Open-label, Randomized, Ph II Clinical Trial Evaluating Safety, and Efficacy of Folfiri with Either Panitumumab or Bevacizumab as Second-Line Treatment in subjects with Metastatic Colorectal Cancer with Wild-Type KRAS Tumors.

03/2007-11/2010

Principal Investigator: A Phase II Trial of Perifosine for Patients with Metastatic Carcinoma of the Kidney who have Progressed on a VEGF Receptor Inhibitor.

06/2007-10/2008

Principal Investigator: A Double Blinded Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib compared to Placebo when Administered in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer.

09/2007-01/2009

Principal Investigator: A Phase I Dose Escalation Study of MK-8033 in Patients with Advanced Solid Tumors.

11/2007-03/2010

Principal Investigator: A Phase I Study of Indibulin in Combination with Erlotinib in Advanced Solid Tumors.

01/2008-01/2009

Principal Investigator: A Randomized, Placebo-Controlled Phase II Study of GDC-0449 (Systemic Hedge Hog Antagonist) With Concurrent Chemotherapy and Bevacizumab as First-Line Therapy for Metastatic Colorectal Cancer.

06/2008-06/2009

Principal Investigator: ZIO-201-T Phase I Study of ZIO-201-T in Combination with Doxorubicin in Subjects with Advanced, Refractory Solid Tumors for which no Stand Therapy Exists and for Whom Treatment with Doxorubicin is Considered Medically acceptable.

06/2008-10/2008

Principal Investigator: Phase II Randomized, Open-Label Study of Cetuximab and Bevacizumab in Combination with Paclitaxel and Carboplatin in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer.

08/2008-01/2009

Principal Investigator: A Multi-Center, Open-Label, Randomized, Phase II Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects with Metastatic Colorectal Cancer with Wild-Type KRAS Tumors.

03/2007-01/2011

Principal Investigator: A Randomized Phase II Study of Erlotinib Plus ARQ 197 vs Erlotinib Plus Placebo In Previously Treated Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC).

10/2008-09/2009

Principal Investigator: A Phase I Investigation of the Safety, Tolerability, and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients with Selected Solid Tumors.

10/2008-01/2010

Principal Investigator: A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults.

06/2008-09/2009

Principal Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer.
06/2008-05/2010

Principal Investigator: A Randomized Placebo-Controlled Study of Perifosine in Combination with Single Agent Chemotherapy for Metastatic Cancer Patient.
02/2007-02/2009

Principal Investigator: A Phase I, Open-Label, Multiple-Dose, Dose Escalation Study of MDX-1342 in Patients with CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia.
01/2009-04/2010

Principal Investigator: A Phase Ib Safety Study of ARQ 197 in Cirrhotic Patients with Hepatocellular Cancer (HCC).
01/2009-08/2009

Principal Investigator: A Phase II Trial of Romidepsin and Bortezomib for Multiple Myeloma Patients with Relapsed or Refractory Disease.
02/2009-01/2010

Principal Investigator: A Phase III, Randomized, Open-Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2-Positive Locally Advanced or Metastatic Breast Cancer.
02/2009-02/2010

Principal Investigator: A Phase I Dose Escalation Study of ARQ 197 Administered in Combination with Gemcitabine in Adult Patients with Advanced Solid Tumors.
03/2009-10/2010

Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination with Temozolomide Versus Temozolomide Alone in Subjects with Metastatic.
03/2009-01/2010

Principal Investigator: Phase I, Open-label, Multicenter, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors.
03/2009-12/2011

Principal Investigator: A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbix) in Combination with Platinum-Based Chemotherapy as First Line Treatment of Patients with Recurrent or Advanced NSCLC (Cetuximab).
09/2009-06/2010

Principal Investigator: A Ib Multiple Ascending Dose Study of BMS-833923 (XL 139) Alone or in Combination with Lenalidomide (Revlimid) plus Dexamethasone or in Combination with Bortezomib (Velcade) in Subjects with Relapsed or Refractory Multiple Myeloma (XL 139).
12/2009-12/2011

Principal Investigator: A Study to Evaluate the Relationship between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients with Advanced Cancer.
01/2010-08/2010

Principal Investigator: Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination with Exemestane in Women with Hormone Receptor-Positive, Advanced Metastatic

Breast Cancer, Women Who have Progressed on a Nonsteroidal Aromatase Inhibitor (BIIB021).
05/2010-11/2010

Principal Investigator: A Phase 1 Study of Oral Darinaparsin in Advanced Solid Tumors.
07/2010-10/2011

Principal Investigator: A Phase 1b, Single-Arm, Open-Label Clinical Trial to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients with HER2-Positive Metastatic or Locally Advanced Inoperable Cancer.
08/2010-12/2011

Principal Investigator: A Randomized Dose Escalation, Safety and Exploratory Efficacy Study of Kanglaite Injection Plus Gemcitabine (G+K) Versus Gemcitabine in Patients with Advanced Pancreatic Cancer.
08/2010-12/2011

Sub-Investigator: A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute®-Pancreas (Algenpantucel-L) Immunotherapy in Subjects with Surgically Resected Pancreatic Cancer. Baylor College of Medicine.
2010-Present

Co-Principal Investigator: An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP with or without Velcade in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma.
01/2011-2011

Principal Investigator: Open-Label, Multicenter Phase 1 Study of Anti-heparin Binding Epidermal Growth Factor-Like Growth Factor (HB-EGF) Monoclonal Antibody KHK2866 as Monotherapy in Subjects with Advanced Solid Tumors and in Combination with Chemotherapy for Epithelial Ovarian, Extra-Ovarian Primary Peritoneal, or Fallopian Tube Cancer (KHK2866).
02/2011-12/2011

Co-Principal Investigator: A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects with Advanced Prostate Cancer without Radiographic Evidence of Metastatic Disease
02/2011-12/2011

Co-Principal Investigator: An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who has Progressed after Taxane-Based Chemotherapy
02/2011-05/2011

Principal Investigator: A Phase I Multicenter, Open-label study of the effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects with Advanced Solid Tumors.
05/2011-12/2011

Principal Investigator: A Phase III Randomized, Placebo-Controlled, Clinical Trial to study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy.
06/2011-12/2011

Principal Investigator: A Randomized Dose Escalation, Safety and Exploratory Efficacy Study of Kanglaite Injection Plus Gemcitabine (G+K) versus Gemcitabine in Patients with Advanced Pancreatic Cancer,
08/2012

Principal Investigator: A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination with Sorafenib Compared to Sorafenib with Placebo in Patients with Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia.
10/2012-2013

Principal Investigator: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy.
11/2012-2014

Principal Investigator: A Phase III, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy.
01/2013-2014

Principal Investigator: MK-3475-002 A Double-Blind, Randomized, Phase II Study of MK3475 versus chemotherapy in Patients with Ipilimumab Refractory Advanced Melanoma.
02/2013-2014

Principal Investigator: Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with or without Trastuzumab in Patients with “Traditional” and “Non-Traditional” HERS2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy.
03/2013-2014

Principal Investigator: A Phase 3, Randomized, Placebo-controlled, Parallel group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refractory to Somatostatin Analog (SSA) Therapy.
07/2013-Present

Principal Investigator: An International Phase 3 Randomized Trial **Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)**.
09/2013-Present

Principal Investigator: A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients with Clinically Progressive Prostate Cancer.
10/2013-Present.

Principal Investigator: Phase I Clinical Trial to Evaluate the Toxicity and Safety of Avelumab (EMR 100070) in Patients with Metastatic or Locally Advanced Solid Tumors.
10/2013-Present.

Grant Reviewer/Service on NIH/Other Study Sections

Member. National Cancer Institute – National Institutes of Health Special Projects Study Section, 2006–present.

Member. External Advisory Board–M.D. Anderson Cancer Center–University of Puerto Rico Cancer Center collaborative U54 grant. 2005 to date.

Member. External Advisory Board – FOX Chase Cancer Center / NCI funded projects for special populations. 2007 to date.

Member. American Society of Clinical Oncology - Scientific Committee – Immunotherapy sub-committee. 2008-2011.

PUBLICATIONS

a. Articles In Peer-Reviewed Journals

1. Camacho LH: Program Death Receptor-1 (PD-1) Pathway inhibition in Cancer Medicine: A Perspective on Clinical Efficacy and Associated Toxicities. **Transl Cancer Res.** 2016 (In

Press).

2. Olszanski AJ, Smith DC, Camacho LH, Thompson J, Ramalingam SS, Harvey RD, Campos L, Ferry D, Tang S, Gao L, Safran H. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. **Oncologist** 2016. Apr;21(4):402-3
3. Sarantopoulos J, Mita MM, Birrer MJ, Cranmer LD, Campos LT, Zhang X, Bristow P, Kaito H, Strout V, Camacho LH. Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. **Target Oncol.** 2016 Jun;11(3):317-27.
4. Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy JA, Kim KB, Hwu WJ, Ribas A. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. **Eur J Cancer** 2015 Nov; 51(17):2689-97.
5. Camacho LH and Pai N: Pharmacovigilance of Oncology Biosimilars. **J Pharmacovigilance** 2015 S3:001 (July 30). Open Access.
6. Camacho LH. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. **Cancer Med.** 2015 May;4(5):661-72.
7. Camacho LH, Frost, CP, Abella E, Morrow PK, Whittaker P. Biosimilars 101: Considerations for U.S. Oncologists in General Practice. **Cancer Med.** 2014 Aug;3(4):889-99.
8. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. **Cancer.** 2014 Jul 15;120(14):2164-73.
9. Pant S, Saleh M, Bendell J, Infante JR, Jones S, Kurkjian CD, Moore KM, Kazakin J, Abbadessa G, Wang Y, Chen Y, Schwartz B, Camacho LH. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors. **Ann Oncol.** 2014 Jul;25(7):1416-21.
10. Mullane KM, Winston DJ, Wertheim MS, Betts RF, Poretz DM, Camacho LH, Pergam SA, Mullane M, Stek JE, Sterling TM, Zhao Y, Manoff SB, Annunziato PW. Safety and Immunogenicity of Heat-Treated Zoster Vaccine (ZVHT) in Immunocompromised Adults. **J Infect Dis.** 208(9):1375-1385, 2013.
11. Santoro A, Simonelli M, Rodriguez-Lope C, Zucali P, Camacho LH, Granito A, Senzer N, Rimassa L, Abbadessa G, Schwartz B, Lamar M, Savage RE, Bruix J. A Phase-Ib Study of Tivantinib (ARQ 197) in Adults Patients with Hepatocellular Carcinoma and Cirrhosis. **Br J Cancer.** 108(1):21-24, 2013.
12. Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Ng CS, Wei W, Johnson MM, Wittemer SM, Vardeleon A, Reckweg A, Colevas AD. JM. A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. **Melanoma Res.,** 22(4):294-301, 2012.
13. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthi S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton, JM. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. **N Engl J Med,** 28;366(26):2455-2465, 2012.

14. Galsky MD, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. **Ann Oncol**, 23(4):1037-1044, 2012.
15. Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. **Clin Genitourin Cancer**, 9(1):27-30, 2011.
16. Naing A, Reuben JM, Camacho LH, Gao H, Lee BN, Cohen EN, Verschraegen C, Stephen S, Aaron J, Hong D, Wheler J, Kurzrock R. Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon alpha for patients with solid tumors. **J Cancer**, 10;2:81-89, 2011.
17. Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho LH, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. **Cancer Chemother Pharmacol**, 66(6):1087-93, 2010.
18. Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. **Clin Colorectal Cancer**, 1;9(5):311-314, 2010.
19. Peguero JS, Camacho LH, Kemp B, Campos LT. Chemokine expression in tumor-to-tumor metastasis. **Oncol Lett**, 1(3):449-452, 2010.
20. Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, Rodriguez MJ, Prieto VG, Glaspy JA, Oseguera DK, Hernandez J, Villanueva A, Chmielowski B, Mitsky P, Bercovici N, Wasserman E, Landais D, Ross MI. Multicenter Phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. **J Transl Med**, 27;8:89, 2010.
21. Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong DS, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. A Phase I study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. **Cancer**, 1;116(17):4086-4094, 2010.
22. Yoon C, Papadopoulos NE, Camacho LH, McIntyre S, Alvarado GC, Bedikian AY, Hwu P, Kim KB. The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. **Melanoma Res**, 20(1):43-47, 2010.
23. Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R. A phase I clinical trial of darinaparsin in patients with refractory solid tumors. **Clin Cancer Res**, 15(14):4769-4776, 2009.
24. Kim KB, Hwu WJ, Papadopoulos NE, Bedikian AY, Camacho LH, Ng C, Hernandez IM, Frost AM, Jack MA, Hwu P. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. **Cancer Chemother Pharmacol**, 64(1):161-167, 2009.
25. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanagui C, Bozon VA, Gomez-Navarro J, Ribas A. Phase I/II Trial of Tremelimumab in patients with metastatic melanoma. **J Clin Oncol**, 1;27(7):1075-1081, 2009.
26. Testori A, Richards J, Whitman E, Mann GB, Lutsky J, Camacho L, Parmiani G, Tosti G,

- Kirkwood JM, Hoos A, Yuh L, Gupta R, Srivastava PK. C-100-21 Study Group. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 Study Group. **J Clin Oncol**, 20;26(6):955-962, 2008.
27. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II trial of imatinib mesylate in patients with metastatic melanoma. **Br J Cancer**, 2;99(5):734-40, 2008.
 28. Torres A, Holoye PY, Camacho LH. Spontaneous Pneumocephalus Associated With Recurrent Colorectal Carcinoma. **J Clin Oncol**, 20;26(33):5483-5484, 2008.
 29. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanahgui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte T lymphocyte-Associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. **J Transl Med**, 1;6:22, 2008.
 30. Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JN. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. **Cancer** 1;112(9):2030-2037, 2008.
 31. Camacho LH. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody. **Expert Opin Investig Drugs**, 17(3):371-385, 2008.
 32. Cormier JN, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Camacho LH, Kim K, Webster K Cella D, Palmer JL. Prospective assessment of the reliability, validity, and sensitivity to change the functional assessment of cancer therapy-melanoma questionnaire. **Cancer**, 15;112(10):2249-2257, 2008.
 33. Camacho LH, Mora-Bowen A, Munden R, Smythe W. R., Ordonez N. G. Malignant mesothelioma: natural history, pathologic features and future therapies. **Am J Med**, 120(7):e7-e9, 2007.
 34. Camacho LH, Kurzrock R, Cheung A, Barber D, Gupta S, Madoff DC, Wallace MJ, Kim EE, Curley SA, Hortobagyi GN, Mavligit G. Pilot study of regional hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. **Cancer**, 109(11):2190-2196, 2007.
 35. Camacho LH, Marubio L, Purdom MA, Leonard D, Hong DS, Moulder S, Pilat, SR, Kurzrock R. Improving the institutional submission, and approval process for clinical research protocols in oncology. **J Clin Oncol**, 20;25(12):1632-1633, 2007.
 36. Shaw SA, Camacho LH, McCutcheon IE, Waguespack SG. Transient hypophysitis after cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade. **J Clin Endocrinol Metab**, 92(4):1201-1202, 2007.
 37. Camacho LH, Olson J, Tong W, et al. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. **Invest New Drugs**, 25(2):131-138, 2007.
 38. Gao Y, Camacho LH, Mehta K. Retinoic acid-induced CD38 antigen promotes leukemia cells attachment and interferon γ /interleukin-1 β -dependent apoptosis of endothelial cells: Implications in the etiology of retinoic acid syndrome. **Leuk Res**, 31(4):455-463, 2007.

39. Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. **Cancer**, 1;106(11):2437-2444, 2006.
40. Bulanlagui, C, Pavlov, D, Ribas, A, Camacho, LH, Gomez-Navarro, Jesus. Objective responses induced by the anti-CTLA4 monoclonal antibody CP-675,206 in patients with melanoma are durable and maintained. **J Immunol**, 29(6), page 634, 2006.
41. Pawlik TM, Zorzi D, Abdalla EK, Clary BM, Gershenwald JE, Ross MI, Aloia TA, Curley SA, Camacho LH, Capussotti L, Elias D, Vauthey J. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. **Ann Surg Oncol**, 13(5):712-720, 2006.
42. Maslak P, Chanel S, Camacho LH, Soignet S, Pandolfi PP, Guernah I, Warrell R, Nimer S. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. **Leukemia**, 20(2):212-217, 2006.
43. Camacho LH, Markman, M. Web Alert. **Current Oncology Reports**, v8, #4, page 239-240, 2006.
44. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanlagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J. Anti-tumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. **J Clin Oncol**, 10:23(35):8968-8977, 2005.
45. Kim KB, Bedikian AY, Camacho LH, Papadopoulos NE, McCullough C. A phase II trial of arsenic trioxide in patients with metastatic melanoma. **Cancer**, 15:104(8):1687-1692, 2005.
46. Camacho LH, Bacik J, Cheung A, Spriggs DR. Presentation and subsequent publication rates of phase I oncology clinical trials. **Cancer**, 1:104(7):1497-1504, 2005.
47. Ballo MT, Zagars GK, Gershenwald JE, Lee JE, Mansfield PF, Kim KB, Camacho LH, Hwu P, Ross MI. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. **Ann Surg Oncol**, 11(12):1079-1084, 2004.
48. Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AY. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. **Cancer**, 1:100(7):1478-1483, 2004.
49. Lovino CS, Camacho LH. Acute myeloid leukemia: a classification and treatment update. **Clin J Oncol Nurs**, 7(5):534-540, 2003.
50. Camacho LH. Clinical applications of retinoids in cancer medicine. **J Biol Regul Homeost Agents**, 17(1):98-114, 2003.
51. Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA, Ellison R, Warrell RP, Jr. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. **J Clin Oncol**, 18(13):2620-2625, 2000.
52. Camacho LH, Wilairatana P, Weiss G, Mercader MA, Brittenham GM, Loareesuwan S, Gordeauk VR. The eosinophilic response and haematological recovery after treatment for plasmodium falciparum malaria. **Trop Med Int Health**, 4(7):471-475, 1999.
53. Camacho LH, Gordeuk VR, Wilairatana P, Pootrakul P, Brittenham GM, Loareesuwan S.

The course of anemia after the treatment of acute, falciparum malaria. **Ann Trop Med Parasitol**, 92(5):525-537, 1998.

b. Abstracts

1. Camacho LH, Semple D, Minsky B, Saltz L. Prior pelvic radiation therapy (PRT) does not contraindicate the use of full starting doses of irinotecan (cpt-11) in patients with recurrent metastatic rectal cancer. **Proc Am Soc Clin Oncol**, 18, Abstract No. 1072, 1999.
2. Novick S, Camacho LH, Ghallager R, et al. Initial clinical evaluation of "transcription therapy" for cancer: all-trans retinoic acid plus phenylbutyrate. **Blood**, 41st Annual ASH meeting, 1999.
3. Camacho LH, Novick S, Tolentino T, Tong W, Richon V, Warrell R Jr. Clinical modulation of gene transcription via inhibition of histone deacetylase using all-trans retinoic acid plus sodium phenylbutyrate. **Proc Am Soc Clin Oncol**, 19(461), Abstract No. 1810, 2000.
4. Bacik J, Camacho LH, Oshalim M, Spriggs DR. Whatever happened to that abstract? An analysis of presentation and publication of phase I trials submitted to an oncology meeting. **Proc Am Soc Clin Oncol**, 20(121), Abstract No. 480, 2001.
5. Camacho LH, Soignet SL, Pezzulli S, et al. Dose escalation study of oral farnesyl transferase inhibitor (FTI) BMS-214662 in patients with solid tumors. **Proc Am Soc Clin Oncol**, 20(79), Abstract No. 311, 2001.
6. Papadopoulos NE, Bedikian AY, Ring S, Kim KB, Camacho LH, Eton O. Phase II study of CTD (cisplatin, paclitaxel, DTIC) in metastatic melanoma (MM). **Proc Am Soc Clin Oncol**, 22(718), Abstract No. 2889, 2003.
7. Kim K, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Ballo MT, Bedikian AY. Biochemotherapy in patients with metastatic anorectal melanoma (MAM). **Proc Am Soc Clin Oncol**, 22(717), Abstract No. 2883, 2003.
8. Camacho LH, Ribas A, Glasoy JA, Lopez-Berenstein G, Reubin J M, Parker C, Seja E, Comin-Anduix B, Bulanhagui CA, Gomez-Navarro J. Phase I Clinical trial of anti-CTLA-4 human monoclonal antibody CP-675,206 (CP-675) in patients (pts) with advanced solid malignancies. **J Clin Oncol, Proc Am Soc Clin Oncol**, 22(14S), Abstract No. 2505, 2004.
9. Harle MT, Cleeland CS, Kim KB, Domine MR, Gning I, Mobley G, Parker CA, Camacho LH. Evaluation of symptom burden in patients receiving concurrent biochemotherapy for metastatic malignant melanoma (MMM). **J Clin Oncol, Proc Am Soc Clin, Oncol**, 22(14S), Abstract No. 6143, 2004.
10. Camacho LH, Kurzrock R, Gutierrez C, Parker C, Purdom MA, Berniger M, Hong DS, Verstovsek S, Gale RP, Lewis JJ. A novel organic arsenic molecule: ZIO-101 (S-dimethylarsino-glutathione): molecular biology and preliminary results of a phase-1 study in solid malignancies. **Proc Am Soc Clin Oncol**, Poster Presentation. 2005.
11. Stewart DJ, Kurzrock R, Oki Y, Kehr K, Gupta S, Wistuba I, Camacho LH, Issa JP. Pharmacodynamics of decitabine 5 days/week x 2 weeks in advanced cancers. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I of II, 23(16S), page 219s, Abstract No. 3110, 2005.
12. Camacho LH, Hawkins KA, Bedikian AY, Papadopoulos NE, Savary C, Ross MI, Lee JE, Gupta R, Srivastava PK. Long term evaluation of patients (pts) with malignant melanoma (MM) treated with autologous cancer vaccine HSPPC-96 at three different dose levels. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I of II, 23(16S), page 722s, Abstract No. 7550, 2005.
13. Reuben JM, Lee BN, Shen DY, Gutierrez C, Hernandez I, Parker CA, Bozon VA, Gomez-Navarro J, Lopez-Bernstein G, Camacho LH. Therapy with human monoclonal anti-CTLA-4

- antibody, CP-675,206, reduces regulatory T cells and IL-10 production in patients with advanced malignant melanoma (MM). **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I of II, 23(16S), page 711s, Abstract No. 7505, page 711s, 2005.
14. Bedikian A, Johnson MM, Broemling LD, Papadopoulos NE, Kim KBS, Camacho LH, Hwu P. Prognostic factors determining long term survival of patients with unresectable stage III and stage IV metastatic melanoma (MM) treated with combination therapy or IL-2 based biochemotherapy (BCC). **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I of II, 23(16S), page 721s, Abstract No. 7544, 2005.
 15. Ribas A, Bozon VA, Lopez-Bernstein, Pavlov D, Reuben JM, Parker CA, Seja E, Glaspy JA, Gomez-Navarro J, Camacho LH. Phase I trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I of II, 23(16S), page 716s, Abstract No. 7524, 2005.
 16. Wang C, Papadopoulos NE, Kim K, Camacho LH, Hwu P, Bedikian AY. A comparison of the outcome of systemic therapy (Rx) of metastatic melanoma of unknown primary site (MUPS) and metastatic mucosal/cutaneous melanoma (MCM). **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I of II, 23(16S), page 721s, Abstract No. 7545, 2005.
 17. Hong DS, Galsky M, Chiorean E, Mulkerian D, Greene D, Nathan FE, Petrone M, Camacho LH. Phase I Study of the effects of renal impairment on the Pharmacokinetic (PK) and safety of satraplatin in patients (pts) with refractory non-hematologic cancer. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 24(18S), page 90s, Abstract No. 2044, 2006.
 18. Camacho LH, Hong DS, Gutierrez C, Vertovsek S, Tannir N, Parker CA, Purdom MA, Lewis J, Gale RP, Kurzrock R. Phase I trial of ZIO-101, a novel organic arsenic in patients with advanced cancers. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 24(18S), page 605s, Abstract No. 13041, 2006.
 19. Braitheh F, Soriano A, Camacho LH, Hong DS, Ng C, Garcia-Manero G, Kurzrock R. Phase I study of low-dose hypomethylating agent azacitidine (5-AC) combined with the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced cancers. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 24(18S), page 135s, Abstract No. 3060, 2006.
 20. Braitheh FS, Yao J, Camacho LH, Ng C, Hong DS, Harris P, Dhillon N, Kurzrock R. Phase I study of the safety and efficacy of atiprimod, a novel azaspirine, for patients with advanced cancer. **J Clin Oncol, Proc Am Soc Clin Oncol**, 24(18S), page 605s, Abstract No. 13050, 2006.
 21. Dhillon N, Wolff RA, Abbruzzese JL, Hong DS, Camacho LH, Li L, Braitheh FS, Kurzrock R. Phase II clinical trial of curcumin in patients with advanced pancreatic cancer. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 24(18S), Abstract No. 14151, page 636s, 2006.
 22. Stewart DJ, Kurzrock R, Yasuhiro O, Camacho LH, Gupta S, Wistuba II, Pilat SR, Zuo Z, Issa JP. Effect of decitabine on DNA methylation in human cancers. **Proc Am Assoc Cancer Res**, 47, page 382, Abstract No. 1616, 2006.
 23. Mavligit G, Kurzrock R, Cheung A, Gupta S, Madoff DC, Wallace M, Kim E, Curley SA, Hortobagyi GN, Camacho LH. Pilot study of regional hepatic intra-arterial (HIA) paclitaxel in patients (pts) with breast carcinoma metastatic to the liver. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 24(18S), Abstract No. 10626, 2006.
 24. Millham R, Pavlov D, Canniff P, Guyot D, Hanson D, Ribas A, Camacho LH, Gomez-Navarro J. Ex vivo blood stimulation assay as a translational research tool in the development of the ticilimumab (CP-675,206). **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 24(18S), page 110s, Abstract No. 2542, 2006.

25. Richards J, Testori A, Whitman E, Mann GB, Lutzky J, Camacho LH, Parmiani G, Hoos A, Gupta R, Srivastava P. Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized phase III trial stage IV melanoma. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 24(18S), page 453s, Abstract No. 8002, 2006.
26. Gomez-Navarro J, Sharma A, Bozon V, Bulanhagui C, Pavlov D, Eck S, Ribas A, Camacho LH. Dose and schedule selection for the anti-CTLA-4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma. **J Clin Oncol, Proc Am Soc Clin Oncol**, 24(18S), Part I, page 460s, Abstract No. 8032, 2006.
27. Ribas A, Comin-Anduix B, Bozon V, Camacho LH, Bulanhagui C, Jalil J, Seja E, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J. Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb ticilimumab. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 24(18S), page 461s, Abstract No. 8033, 2006.
28. Papadopoulos NE, Eton E, Kim KB, Camacho LH, Hwu P, Bedikian AY. Phase II study of 'hybrid' biochemotherapy for advanced melanoma. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 24(18S), page 686s, Abstract No. 18007, 2006.
29. Bulanhagui C, Ribas A, Pavlov D, Bozon V, Sharma A, Gomez-Navarro J, Camacho LH. Phase I clinical trials of ticilimumab: Tumor responses are sufficient but not necessary for prolonged survival. **Proc Am Soc Clin Oncol**, 24(18S), page 461s, Abstract No. 8036, 2006.
30. Noe D, Pavlov D, Ribas A, Camacho LH, Gomez-Navarro J, Sharma A. Anti-tumor effect of CP-675,206 in melanoma relates to systemic exposure. **Clin Cancer Res**, 2007.
31. Camacho LH, Naing A, Verschraegen C, Meric-Bernstam F, Hong D, Moulder S, Gutierrez C, Stephen S, Chandhasin C, Gao H, Cohen E, Lee BN, Martinez M, Akinsanmi L, Kurzrock R, Reuben J. Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, in combination with interferon- α for patients with solid tumors. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA., Poster Presentation, **AACR**, Abstract No. B89, 2007.
32. Camacho LH, Ryan J, Chanel S, et al. Transcription Modulation: A Pilot Study of Sodium Phenylbutyrate Plus 5-Azacytidine. **Blood**, 10.1182, 03, 078576, 2007.
33. Ross M, Camacho LH, Hersch EM, Brown CK, Richards J, Mitsky P, Wasserman E, Lee S, Bercovici N, Landais D, Ribas A. Clinical and Immunological responses in patients with malignant melanoma treated with a dendritic cell-based vaccine. Preliminary report from a multi-institutional phase II clinical trial. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 25(18S), page 119s, Abstract No. 3004, 2007.
34. Bulanhagui C, Ribas A, Pavlov D, Gomez-Navarro J, Camacho LH. Retrospective analysis of thyroid abnormalities in patients with cancer treated with tremelimumab (CP-675,206). **J Clin Oncol**, Abstract No. 3247, 2007.
35. Antonia S, Sosman J, Kirkwood JM, Redman B, Gajewski, TF, Pavlov D, Bulanhagui C, Camacho LH, Ribas A. Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody (CP-675,206). **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 25(18S), page 127s, Abstract No. 3038, 2007.
36. Soriano AO, Braitheh F, Garcia-Manero G, Camacho LH, Hong DS, Moulder S, Ng C, Kurzrock R. Combination of 5-azacytidine (5-AZA) and valporic acid (VPA) in advanced solid cancers: A phase I study. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 25(18S), page 149s, Abstract No. 3547, 2007.
37. Camacho LH, Hong DS, Gutierrez C, Parker CA, Purdom MA, Tannir NM, Moulder S, Gale RP, Schwartz B, Kurzrock R. Poster Discussion: Organic arsenic in patients (pts) with

- advanced solid tumors: Phase 1 of results Zio101 (s-dimethylarsino-glutathione). **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 25(18S), page 151s, Abstract No. 3554, 2007.
38. Dhillon N, Aggarwal B.B, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Hong DS, Camacho LH, Ng C, Kurzrock R. Curcumin and pancreatic cancer: Phase II clinical trial experience. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 25(18S), page 222s, Abstract No. 4599, 2007.
 39. Dhillon N, Moulder S, Hong D, Ng C, Camacho LH, Hersh E, Grenier K, Dorr R, Kurzrock R. Phase I trial of imexon and docetaxel in patients with previously-treated stage IV non-small cell lung cancer, metastatic breast cancer or hormone-refractory prostate cancer. 98th AACR Annual Meeting, Los Angeles, CA, Poster Presentation, **AACR**, Abstract No. LB-351, 2007.
 40. Gomez-Navarro J, Antonia S, Sosman J, Kirkwood JM, Redman B, Gajewski TF, Pavlov D, Bulanahgui C, Ribas A, Camacho LH. Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 Monoclonal antibody (mAb) CP-675,206 in phase I/II study. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 25(18S), page 478s, Abstract No. 8524, 2007.
 41. Kim KB, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Johnson MM, Colevas AD, Prieto VG. A randomized phase II study of EMD 121974 in patients (pts) with metastasis melanoma (MM). **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 25(18S), page 484s, Abstract No. 8548, 2007.
 42. Cormier JN, Webster K, Cella D, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Kim KB, Camacho LH, Palmer JL. Reliability and validity of the Functional Assessment of Cancer Therapy-melanoma (FACT-M). **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 25(18S), page 485s, Abstract No. 8554, 2007.
 43. Salgia R, Hong DS, Camacho LH, Ng, CS, Janisch L, Ratain MJ, Kurzrock R. A phase I dose escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 25(18S), page 614s, Abstract No. 14031, 2007.
 44. Dezube BJ, Kurzrock R, Eder JP, Supko JG, Meyer CJ, Camacho LH, Andreeff M, Konopleva M, Lescale-Matys L, Hong D. Interim results of a phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 25(18S), page 619s, Abstract No. 14101, 2007.
 45. Kurzrock R, Akerley W, Hong D, Ng C, Warren T, Zavitz K, McCage C, Laughlin M, Camacho LH. Two phase 1 studies of MPC-6827, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors and CNS metastases. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 25(18S), Abstract No. 3604, 2007.
 46. Falchook GS, Dhillon N, Moulder S, Duvic M, Ng C, Hong DS, Camacho LH, Lim J, Wang M, Fayad L, Kurzrock R. Age-Stratified phase I trial of a combination of borteomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 25(18S), Abstract No. 14087, 2007.
 47. Ribas A, Antonio S, Sosman J, Kirkwood JM, Redman B, Gajewski TF, Pavlov D, Bulanahgui C, Gomez-Navarro J, Camacho LH. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (patients) with advanced melanoma. **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 25(18S), Abstract No. 3000, 2007.
 48. Camacho LH, Garcia S, Jarvis A, Patterson M, Lim J, Hovden M, Madoff DC, Wallace M,

Hong D, Kurzrock R. Hepatic arterial oxaliplatin in combination with systemic intravenous fluorouracil and bevacizumab for cancer patients with advanced refractory liver metastasis. **2nd Regional Cancer Therapies 2007 Conference.**

49. Hong DS, Camacho LH, Ng C, Wright J, Newman RA, Moulder S, Tannir N, Wheler J, Khan R, Kurzrock RA. Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancers (NCI protocol 7156 supported by NCI grant UO1 CA062461). **J Clin Oncol, Proc Am Soc Clin Oncol**, Part I, 25(18S), Abstract No. 3549, 2007.
50. Moulder SL, Dhillon N, Hong DS, Ng CS, Camacho LH, Hersh EM, Grenier KA, Boytim ML, Dorr RT, Kurzrock R. A phase I study of imexon in combination with docetaxel (DOC) for the treatment of patients with breast, lung and prostate cancer. **J Clin Oncol**, Abstract No. 3589, 2008.
51. Naing A, Reuben J, Verschraegen C, Camacho LH, Stephen S, Hong DS, Wheler J, Fu S, Martinez M, Akinsanmi L, Kurzrock R. Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon alfa for patients with solid tumors. **J Clin Oncol**, 26(15S), Abstract No. 3011, 2008.
52. Bulanhagui CA, Gomez-Navarro J, Antonia S, Sosman J, Kirkwood JM, Redman B, Gajewski TF, Ribas A, Camacho LH, Pavlov D. Prognostic role of prior cytokine immunotherapy in outcome of treatment with tremelimumab (CP-675,206) in patients with metastatic melanoma. **J Clin Oncol**, 26(15S), Abstract No. 3057, 2008.
53. Camacho LH, Moulder S, LoRusso P, Blumenschein GR, Bristow P, Kurzrock R, Fu S, Schlienger K, Bergstrom DA, First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors. **J Clin Oncol**, Abstract No. 14657, 2008.
54. Mutha P, Camacho LH, Madoff DC, Gupta S, Murthy R. Can percutaneous hepatic artery infusional chemotherapy procedures be safely performed with concomitant systemic bevacizumab therapy? **3rd Regional Cancer Therapies 2008 Conference.**
55. Testori A, Richards J, Whitman E, Bruce Mann G, Lutzky, Camacho LH, Parmiani G, Tosti G, Kirkwood JM, Hoos A, Yuh L, Gupta R, Srivastava PK. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 Study Group. **J Clin Oncol**, 26(6), pages 955-962, Abstract No. 3819, 2008.
56. Camacho LH, Chawla SP, Chua V, Abbadessa G, Komarintsky PB, Lewis JJ. A Phase I study of palifosfamide in combination with doxorubicin: safety and preliminary efficacy. **J Clin Oncol**, 27(15S), Abstract No. 10577, 2009.
57. Lewis JJ, Galsky MD, Camacho LH, Loesch DM, Komarintsky PB, Norton, L. Evaluation of indibulin, a novel targeting-agent, in combination with capecitabine, with mathematically optimized dose scheduling. **J Clin Oncol**, 27(15s), Abstract No. 2538, 2009.
58. Zucali P, Santoro A, Rodriguez-Lope C., Simonelli, M. Camacho, LH., Senzer NN., Bolondi L, Lamar M, Abbadessa BE. Final results from ARQ 197-114: A Phase 1b safety trial evaluating ARQ 197 in cirrhotic patients (patients) with hepatocellular carcinoma (HCC). **J Clin Oncol**, 28(15s), Abstract No. 4137, 2010.
59. Camacho LH, Bendell JC, John-Reid L, Campos LT, Jones SF, Kazakin J, Savage R, Schwartz BE, Abbadessa G, Saleh MN; Phase Ib dose-escalation trial evaluating c-MET inhibitor ARQ 197 administered in combination with gemcitabine to patients (pts) with advanced solid tumors. **J Clin Oncol**, Abstract No. e13008, 2010.
60. Camacho LH, Bendell JC, John-Reid L, Campos LT, Jones SF, Kazakin J, Savage R,

- Schwartz BE, Abbadessa G, Saleh MN. Phase Ib results of c-MET inhibitor ARQ 197 in combination with gemcitabine in a cohort of patients (pts) with advanced breast, ovarian, and uterine tumors. **J Clin Oncol, Proc Am Soc Clin Oncol**, 28(15), Abstract No. 3077, 2010.
61. Santoro A, Simonelli M, Zucali P, Rimassa L, Senzer NN, Camacho LH, Bolondi L, Lamar M, Abbadessa G, Bruix J. A phase Ib safety trial of ARQ 197 in cirrhotic patients with hepatocellular carcinoma (HCC). **J Clin Oncol**, Abstract No. 187, 2010.
 62. Simonelli M, Rodriquez, Lope C, Rimassa L, Bolondi L, Camacho LH, Senzer NN, Abbadessa G, Waghorne C, Santoro A, Bruix J. (Poster Results) Biomarker results from ARQ 197-114: A Phase 1b trial evaluating the cMET Inhibitor ARQ 197 in cirrhotic patients (PTS) with hepatocellular carcinoma (HCC). 2010.
 63. Mullane K, Winston D, Wertheim M, Betts R, Poretz D, Camacho LH, Pergam S, Sterling T, Zhao Y, Manoff S. Safety and immunogenicity of heat-treated zoster vaccine (ZV_{HT}) in Immunocompromised (IC) Adults. **ISDA Annual Meeting 2010**. Abstract No. 1379, 2010.
 64. Camacho LH, Pant S, Saleh MN, Abbadessa G, Kazakin J, Schwartz BE, Bendell JC. Phase 1b results of c-Met inhibitor ARQ 197 in combination with gemcitabine in a cohort of patients (patients) with advanced breast, ovarian, and uterine tumors. **J Clin Oncol**, 29, Abstract No. 3077, 2011.
 65. Huff C, Padmanabhan S, Kelly K, Somlo G, Camacho LH, Zonder J, Fischer B, Lang L, Zhang S, Gestone T, Bennett KL. CA194-003: A Phase Ib Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination with Lenalidomide (Revlimid) plus Dexamethasone or in Combination with Bortezomib (Velcade) in Subjects with Relapsed or Refractory Multiple Myeloma. **ASH**, Poster. 2011.
 66. Camacho LH, Senzer NN, Harb WA, Barrett JA, Korth CC, Astl D, Jac J, Youssoufian H. A phase I study of oral darinaparsin in patients (pts) with advanced solid tumors (AST). **J Clin Oncol** 30, Abstract No. 13040, 2012.
 67. Tykodi SS, Brahmer JR, Hwu WJ, Chow LQ, Topalian SL, Hwu P, Odunsi K, Camacho LH, Kauh JS, Pitot HC, Hamid O, Pardoll DM, Agrawal S, Parker S, Goldberg S, Gupta AK, Wigginton J. PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. **J Clin Oncol** 30, Abstract No. 2510, 2012.
 68. Reul M, Camacho LH, Jasqui S, Pedraza R, Rajiman I, Haas EM. Adult Intestinal Burkitts Lymphoma: To Cut or Not to Cut? Texas Society of Clinical Oncology – Annual Meeting. 2012.

c. Book Chapters

Camacho LH. Melanoma. In: Multidisciplinary Care of Head and Neck Cancer. Web Book 2005. 2nd Edition. (Chapter 13). <http://headneckcancer.bedecker.com/>

Camacho LH. Drug Development in Cancer Medicine: Challenges for Targeted Approaches. Current Clinical Oncology. Target Cancer Therapy (Chapter 19), pp. 383-410. 2008.

EDITORIAL AND REVIEW ACTIVITIES

Journal Reviewer

Journal of Clinical Oncology
Cancer
Clinical Cancer Research
Melanoma Research
Immunology Immunotherapy

Clinical Medicine Insights - Blood Disorders
Clinical Medicine Insights - Oncology
Clinical Medicine Reviews in Oncology
Clinical Medicine Reviews in Therapeutics
Drugs of the Future
Immune Investigation
Journal of Translational Medicine
Cancer
Translational Cancer Research

Journal Editor

Med. Medical Journal of Universidad Militar “Nueva Granada”.

TEACHING EXPERIENCE

University of Texas M.D. Anderson Cancer Center.

Co-Director, Human Cancer Immunotherapy Course.
Graduate School of Biomedical Sciences
University of Texas M.D. Anderson Cancer Center.2002-2007

Direct Supervision

Department of Medicine House Staff Monthly Lectures. Hypercoagulability and Cancer. Memorial Sloan-Kettering Cancer Center, 06/1999-06/2001.

Medical Students

Joan and Sanford I. Weill Medical College of Cornell University, Physical Examination Preceptorship, Second Year Medical Students, 01/2001-03/2001.

PRESENTATIONS AT NATIONAL OR INTERNATIONAL CONFERENCES

1. “Preparing the Test: Pearls for Success”. A Comprehensive Board Review in Hematology and Medical Oncology Course”, The University of Texas M.D. Anderson Cancer Center, Houston, TX. October 2002.
2. “Nuevas Terapias en Cáncer”. National Meeting of the Colombian Association of Internal Medicine, Cartagena, Colombia. October 2002.
3. “Avances en tumores sólidos / Trombosis en Cáncer”. National Meeting of the Colombian Association of Internal Medicine, Cartagena, Colombia. October 2002.
4. “CTLA4 Blockade as Anti-Cancer Therapy”. Medical Grand Rounds, Post Oaks Medical Center, Houston, TX. March 2003.
5. “Terapia Antioangiogénica y Factor de Crecimiento epidérmico como blanco de terapia”. Congreso Annual de la Sociedad Americana de Oncología Clínica, Chicago, IL. May 2003.
6. “Apoptosis”. Congreso Anual de al Sociedad Americana de Oncología Clínica, Chicago, IL. May 2003.
7. “Aspectos en el manejo actual del Melanoma Maligno Metastásico”. Congreso Annual de al Sociedad Americana de Oncología Clínica, Chicago, IL. May 2003.
8. “Terapia Antioangiogénica y Factor de Crecimiento epidérmico como blanco de terapia”. Post ASCO Conference, Santa Marta, Colombia, August 2003.
9. “New Cancer Therapies”. 2003 Annual New Horizons, The University of Texas M. D. Anderson Cancer Center Houston, TX. September 2003.
10. “Preparing the Test: Pearls for Success”. A Comprehensive Board Review in Hematology and Medical Oncology Course. The University of Texas M. D. Anderson Cancer Center Houston, TX. October 2003.

11. "Regional Immunotherapy, Oncologic Interventional Radiology: A Multidisciplinary Approach". The University of Texas M. D. Anderson Cancer Center, The Woodlands, TX. January 2004.
12. "Malignant Melanoma: Are We Leaving the Dark Spot?". Grand Rounds, The University of Texas M. D. Anderson Cancer Center, Gulf Coast Regional Hospital, Wharton, TX. January 2004.
13. "Evoking Medawar: Novel Therapies against Malignant Melanoma". Disease Management Team Conference. Memorial Sloan-Kettering Cancer Center, New York, NY. March 2004.
14. "Phase I Clinical Trial of Anti-CTLA4 Human Monoclonal Antibody CP-675, 206 in Patients with Advanced Solid Malignancies". ASCO. May 2004.
15. "Phase I Clinical Trial of Anti-CTLA4 Human Monoclonal Antibody CP-675, 206 in Patients with Advanced Solid Malignancies". Pfizer, Oncology Scientific Colloquium, New Orleans, LA. June 2004.
16. "Melanoma: Questions and Answers". A Comprehensive Board Review in Hematology and Medical Oncology Course, The University of Texas M.D. Anderson Cancer Center, Houston, TX. September 2004.
17. "Phase I Clinical Trial of Anti-CTLA4 Human Monoclonal Antibody CP-675, 206 in Patients with Advanced Solid Malignancies". 4th International Congress on Monoclonal Antibodies in Cancer, Colorado Springs, CO. September 2004.
18. "Importance of Clinical Trials in Cancer Medicine". Syncure Update 2004: Cancer Research and Treatment, McHenry, IL. September 2004.
19. A-3671002 Update, Pfizer Data Meeting, New London, CT. November 2004.
20. "Gastrointestinal Toxicity after CTLA4 Blockade with CP-675,206". The Pfizer GI Symposium, New York, NY. November 2004.
21. "Drug Development: Clinical Trials in Cancer Medicine". Academic Orientation Conference, San Juan, Puerto Rico, University of Puerto Rico Comprehensive Cancer Center Phase I Program at the University of Texas M.D. Anderson Cancer Center. February 2005.
22. "CTLA4 Blockade Therapy Clinical and Immunology Overview". Melanoma: Update on Diagnosis and Treatment, Houston, TX. February 2005.
23. "New Cancer Therapies". First International Conference, Advances in Oncology, Lima, Peru. March, 2005.
24. "HSPPC-96 Clinical Trials and Potential in Melanoma". Second International Symposium on Melanoma, New York, NY. April, 2005.
25. 5th International Congress on "Monoclonal Antibodies in Cancer". Quebec, Canada. August, 2005.
26. 4th International Targeted Therapy Congress. Washington, DC. August, 2005.
27. "Systemic Therapies for Malignant Melanoma". 7th Annual Melanoma Symposium. Orange County, CA. May, 2006.
28. "Selective Molecular Targets in Malignant Melanoma". IV Curso Interdisciplinario de Oncologia. Oviedo, Spain. May 2006.

29. "CTLA4 antibodies in Kidney Cancer". 4th International Congress on Kidney and Bladder Cancer. Orlando, Fl. August 2006.
30. "Novel Drugs in Cancer Therapy". Grand Rounds. Victoria Medical Center. Victoria, TX. September 2006.
31. "Designing Investigation in Cancer". Annual Congress of the Colombian Society of Hematology and Oncology. Bogotá, Colombia. November 2006.
32. "Anti-CTLA4 Antibodies in Cancer". Antibody Therapeutics. 3rd Annual International Conference. San Diego CA. December 2006.
33. "Novel Cancer Therapies: CTLA4 Blockade". Grand Rounds at Howard University, Washington, D.C. February 2007.
34. "HAI Oxaliplatin In Combination With Systemic And 5-FU and Bevacizumab for Cancer Patients With Advanced Refractory Liver Metastasis Conference and Faculty". Second International Symposium on Regional Cancer Therapies. San Juan, Puerto Rico. February 2007.
35. "Development of Anti-Cancer Therapies, A Perspective, and Future Challenges". Hackensack University Medical Center Grand Rounds. Hackensack, New Jersey. April 2010.
36. "Development of Anti-Cancer Therapies, A Perspective, and Future Challenges. St. Luke's Episcopal Hospital Cancer Center, Texas Medical Center. Houston, Texas. Grand Rounds. June 2010.
37. "Phase 1b Results of c-MET Inhibitor ARQ 197 in Combination with Gemcitabine (Gem) in a Cohort of Patients (pts) with Advanced Thoracic Tumors". 14th World Conference on Lung Cancer (WCLC). RAI Convention Centre in Amsterdam, The Netherlands July 2011.
38. A Comprehensive Board Review in Hematology and Medical Oncology Course, The University of Texas M.D. Anderson Cancer Center, Houston, TX. September 2011.
39. "Hepatocellular Carcinoma: Novel Directed Therapies". Arab Health 2012 Conference. Dubai, United Arab Emirates. January 2012.
40. "Colorectal Liver Metastasis". Arab Health 2012 Conference. Dubai, United Arab Emirates. January 2012.
41. "Basic Concepts in Cancer Medicine". National Meeting of the Labanese Society. Mexico DF. October 2012.
42. Plenary Session: "Novel Targeted Therapies to Follow in 2012-2013". Colombian Society of Hematology and Oncology National Meeting. Medellin, Colombia. November 2012.
43. Melanoma Session: "Current Status and Future Treatments for Metastatic Melanoma". Colombian Society of Hematology and Oncology National Meeting. Medellin, Colombia. November 2012.
44. Melanoma Session: "Management of Immune Related Toxicities". Colombian Society of Hematology and Oncology National Meeting. Medellin, Colombia. November 2012.
45. "Hepatic Carcinoma: Novel Targeted Therapies in Research Opportunities". Hepatology/Liver Transplantation Conference. St. Luke's Episcopal Hospital, Texas Medical Center. Houston, Texas. December 2012.

46. "Rectal Cancer: State of the Art and Future Opportunities". The Arab Health Congress Oncology Conference: Colorectal / GI Cancer & Breast Cancer. Dubai, United Arab Emirates. January 2013.
47. "Early Drug Development in Cancer Medicine: Understanding and Design of Phase 0 and Clinical Trials". Course of Molecular Biology, Diagnosis and Research for Hematologists and Oncologists. Bogota, Colombia. February – March 2013.
48. "Tumor Tissue Banking: Phase II Clinical Trials and Bio-banking Importance for Research in Hematology and Oncology". Course of Molecular Biology, Diagnosis and Research for Hematologists and Oncologists. Bogota, Colombia. February – March 2013
49. "Building Bridges Across Institutions". Cancer Research at the SLEH Cancer Center: Cancer Research Summit. St. Luke's Episcopal Hospital, The Texas Medical Center. Houston, Texas. March 2013.
50. "All About Cancer". Petrobras America Health Week, Houston, Texas. April 2013
51. "Research Today – On the Market Tomorrow, An Update in Clinical Research". Clinical Research Symposium. St. Luke's Episcopal Hospital, The Texas Medical Center Houston, Texas. May 2013.
52. Pfizer - St. Luke's Episcopal Hospital Video Conference Lecture Series. St. Luke's Episcopal Hospital, Texas Medical Center. Houston, Texas. May 2013.
53. "Papel de la Inmunoterapia en el Tratamiento de Tumores Sólidos". Sociedad Colombiana de Hematología y Oncología. Cartagena, Colombia. August 2013.
54. "Estudios Oncológicos de Fase 1 y 2 en Colombia". Sociedad Colombiana de Hematología y Oncología. Cartagena, Colombia. August 2013.
55. "Skin Cancer – General Principles". Phillips 66 Headquarters. Houston, Texas. September 2013.
56. "Integrative Medicine Therapies: Past and Present Challenges". Centro para el Desarrollo de la Mujer. Cuerpo-Mente-Espiritu. Integrative Medicine. Houston, Texas. September 2013.
57. "Integrative Medicine Therapies: Past and Present Challenges". Congreso de Oncología Integrativa. Cali, Colombia. September 2013.
58. "Implementación & Entrenamiento en Oncología Integrativa". Congreso de Oncología Integrativa. Cali, Colombia. September 2013
59. "Targeted Therapies in Hepatocellular Carcinoma (HCC)". Hepatology/Liver Transplantation Conference. CHI BCM St. Luke's Medical Center. Houston, Texas. October 2013.
60. "Papel de la Inmunoterapia en el Tratamiento de Tumores Sólidos". Simposio International Actualización en Oncología, Tegucigalpa, Honduras. December 2013.
61. "Implementación & Entrenamiento en Oncología Integrativa". Simposio International Actualización en Oncología, Tegucigalpa, Honduras. December 2013.
62. "Medicina de Cancer". Simposio International Actualización en Oncología, Tegucigalpa, Honduras. December 2013.
63. "Recent Advances in Immunotherapy: Immune Checkpoint Inhibitors". The Arab Health Congress Oncology Conference: Colorectal / GI Cancer & Breast Cancer. Dubai, United Arab Emirates. January 2014.

64. "Advances in Immunotherapy: Immune Checkpoint Inhibitors". 31a Reunión Anual Médica del INC. Immunoterapia Y Cáncer / Immunotherapy and Cancer. Monterrey, MX. February 2014.
65. "Evaluation of Upcoming Clinical Trials". Hepatology/Liver Transplantation Conference. CHI St. Luke's Health-Medical Center | Baylor St. Luke's Medical Center. February 2014.
66. "Immunotherapy in the Treatment of Cancer: State-of-the-Art". 4a Reunión Internacional de Expertos en Melanoma. Cancún, MX / Puerto Morelos, MX. March 2014.
67. "Criterios de Respuesta a los Nuevos Tratamientos del Cancer". 4a Reunión Internacional de Expertos en Melanoma. Cancún, MX / Puerto Morelos, MX. March 2014.
68. "Advances in Immunotherapy for Lung Cancer". XXXII Congreso Nacional de Oncología. Ixtapa, MX. October 2014.
69. "Biosimilars in Oncology". Symposium: *Beyond the Looking Glass: Biosimilars in Cancer Care*. Chicago, IL. June 2015.
70. "Inmunoterapia para Cáncer de Pulmón" LVIII Congreso Médico Nacional de Honduras. Tegucigalpa, Honduras. July 2015.
71. "Biosimilars in Oncology" LVIII Congreso Médico Nacional de Honduras. Tegucigalpa, Honduras. July 2015.
72. "Advances in Immuno-Oncology". Clínica de Mérida. Mérida, Mexico. August 2016

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

National and International

- American Medical Association, 1995-present.
- Resident's Committee. GME. The George Washington University, 1995
- American College of Physicians /American Society of Internal Medicine, 1996-present.
- American Society of Clinical Oncology, 1999-present.
- American Association for Cancer Research, 2000-present.
- American Society of Hematology, 2000-present.
- Texas Society Clinical Oncology, (TxSCO), (Formerly TSMO) 2007-present